110 related articles for article (PubMed ID: 27416702)
21. The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.
Recknor CP; Recker RR; Benson CT; Robins DA; Chiang AY; Alam J; Hu L; Matsumoto T; Sowa H; Sloan JH; Konrad RJ; Mitlak BH; Sipos AA
J Bone Miner Res; 2015 Sep; 30(9):1717-25. PubMed ID: 25707611
[TBL] [Abstract][Full Text] [Related]
22. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis.
Chen H; Xu X; Liu M; Zhang W; Ke HZ; Qin A; Tang T; Lu E
Bone; 2015 Jul; 76():141-8. PubMed ID: 25868799
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing.
Agholme F; Macias B; Hamang M; Lucchesi J; Adrian MD; Kuhstoss S; Harvey A; Sato M; Aspenberg P
J Orthop Res; 2014 Mar; 32(3):471-6. PubMed ID: 24243768
[TBL] [Abstract][Full Text] [Related]
24. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women.
McColm J; Hu L; Womack T; Tang CC; Chiang AY
J Bone Miner Res; 2014 Apr; 29(4):935-43. PubMed ID: 23996473
[TBL] [Abstract][Full Text] [Related]
25. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders.
Vervloet MG; Massy ZA; Brandenburg VM; Mazzaferro S; Cozzolino M; Ureña-Torres P; Bover J; Goldsmith D;
Lancet Diabetes Endocrinol; 2014 May; 2(5):427-36. PubMed ID: 24795256
[TBL] [Abstract][Full Text] [Related]
26. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis.
Eddleston A; Marenzana M; Moore AR; Stephens P; Muzylak M; Marshall D; Robinson MK
J Bone Miner Res; 2009 Oct; 24(10):1662-71. PubMed ID: 19419292
[TBL] [Abstract][Full Text] [Related]
27. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
28. From Bone Cell Biology to Novel Therapies of Osteoporosis.
Hofbauer LC
Drug Res (Stuttg); 2015 Nov; 65 Suppl 1():S14-5. PubMed ID: 26536179
[No Abstract] [Full Text] [Related]
29. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
[TBL] [Abstract][Full Text] [Related]
30. Sclerostin antibody prevents particle-induced implant loosening by stimulating bone formation and inhibiting bone resorption in a rat model.
Liu S; Virdi AS; Sena K; Sumner DR
Arthritis Rheum; 2012 Dec; 64(12):4012-20. PubMed ID: 23192793
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effect of omega-3 fatty acids on bone metabolism.
McMahon MS
Orthopedics; 2012 Sep; 35(9):735-6. PubMed ID: 22955379
[No Abstract] [Full Text] [Related]
32. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
Hofbauer LC; Schoppet M
JAMA; 2004 Jul; 292(4):490-5. PubMed ID: 15280347
[TBL] [Abstract][Full Text] [Related]
34. [Anti-RANKL antibody].
Fukuhara T; Maemondo M
Nihon Rinsho; 2015 Feb; 73 Suppl 2():235-9. PubMed ID: 25831759
[No Abstract] [Full Text] [Related]
35. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus.
Hamann C; Rauner M; Höhna Y; Bernhardt R; Mettelsiefen J; Goettsch C; Günther KP; Stolina M; Han CY; Asuncion FJ; Ominsky MS; Hofbauer LC
J Bone Miner Res; 2013 Mar; 28(3):627-38. PubMed ID: 23109114
[TBL] [Abstract][Full Text] [Related]
36. [Update and perspectives of anabolic therapies for osteoporosis].
Endo I; Matsumoto T
Clin Calcium; 2012 Mar; 22(3):327-33. PubMed ID: 22370299
[TBL] [Abstract][Full Text] [Related]
37. Sclerostin antibody treatment enhances metaphyseal bone healing in rats.
Agholme F; Li X; Isaksson H; Ke HZ; Aspenberg P
J Bone Miner Res; 2010 Nov; 25(11):2412-8. PubMed ID: 20499342
[TBL] [Abstract][Full Text] [Related]
38. Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats.
Suen PK; Zhu TY; Chow DH; Huang L; Zheng LZ; Qin L
Sci Rep; 2015 Oct; 5():15632. PubMed ID: 26494536
[TBL] [Abstract][Full Text] [Related]
39. [Denosumab as the potent therapeutic agent against Paget's disease of bone].
Hirao M; Hashimoto J
Clin Calcium; 2011 Aug; 21(8):1231-8. PubMed ID: 21814030
[TBL] [Abstract][Full Text] [Related]
40. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
